Tania E Mesa
Overview
Explore the profile of Tania E Mesa including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
203
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gillis N, Dickey B, Colin-Leitzinger C, Tang Y, Putney R, Mesa T, et al.
J Infect Dis
. 2024 Apr;
230(3):680-688.
PMID: 38657098
Background: Cancer-related deaths for people with human immunodeficiency virus (PWH) are increasing due to longer life expectancies and disparately poor cancer-related outcomes. We hypothesize that advanced biological aging contributes to...
2.
Bagchi P, Boukli N, Browner N, Daria D, Griffiths L, Mesa T, et al.
J Biomol Tech
. 2023 Apr;
34(1).
PMID: 37089872
[audio element].
3.
Seagroves T, Bagarozzi D, Bagchi P, Boukli N, Browner N, Colton-Lee F, et al.
J Biomol Tech
. 2022 Jul;
32(4).
PMID: 35837271
No abstract available.
4.
Herbert Z, Thimmapuram J, Xie S, Kershner J, Kolling F, Ringelberg C, et al.
J Biomol Tech
. 2020 Jan;
31(2):47-56.
PMID: 31966025
Small RNAs (smRNAs) are important regulators of many biologic processes and are now most frequently characterized using Illumina sequencing. However, although standard RNA sequencing library preparation has become routine in...
5.
Sun J, Chen D, Li J, Sun W, Yoder S, Mesa T, et al.
J Surg Res
. 2019 Aug;
245:153-162.
PMID: 31419640
Background: Breast cancer (BC) risk assessment models are statistical estimates based on patient characteristics. We developed a gene expression assay to assess BC risk using benign breast biopsy tissue. Methods:...
6.
Coombs C, Gillis N, Tan X, Berg J, Ball M, Balasis M, et al.
Clin Cancer Res
. 2018 Jun;
24(23):5918-5924.
PMID: 29866652
Purpose: In this era of precision-based medicine, for optimal patient care, results reported from commercial next-generation sequencing (NGS) assays should adequately reflect the burden of somatic mutations in the tumor...
7.
Gillis N, Rotroff D, Mesa T, Yao J, Chen Z, Carulli M, et al.
Oncotarget
. 2018 Feb;
8(70):115114-115127.
PMID: 29383146
Multi-targeted tyrosine kinase inhibitors (TKIs) have broad efficacy and similar FDA-approved indications, suggesting shared molecular drug targets across cancer types. Irrespective of tumor type, 20-30% of patients treated with multi-targeted...
8.
Gillis N, Ball M, Zhang Q, Ma Z, Zhao Y, Yoder S, et al.
Lancet Oncol
. 2016 Dec;
18(1):112-121.
PMID: 27927582
Background: Clonal haemopoiesis of indeterminate potential (CHIP) is an age-associated genetic event linked to increased risk of primary haematological malignancies and increased all-cause mortality, but the prevalence of CHIP in...